Overview
Mindstate Design Labs creates targeted mental health therapies by designing altered states of consciousness through its Osmanthus platform, which predicts how primer psychedelic compounds and non-psychedelic probe compounds interact to produce specific therapeutic states. The platform blends natural history data, natural language processing, and biochemical data to build a predictive model that guides the design and pairing of these compounds. Unlike others who mainly develop psychedelics, Mindstate Design focuses on a translational framework that distinguishes between different altered states and tailors them for therapy. The company aims to license its primer and probe compounds to healthcare and pharmaceutical clients to advance psychedelic medicine.
Work here?Claim your company
Simplify's take
What believers are saying
- September 2025 Phase 1 data showed MSD-001 was safe, well tolerated, and non-hallucinogenic.
- Mindstate raised $24.33 million by November 2026, funding ongoing clinical expansion.
- The October 2026 DEA hearing challenge may preserve research freedom for 5-MeO-MiPT programs.
What critics are saying
- DEA Schedule I action on 5-MeO-MiPT would cripple MSD-001 development in 2027.
- One lead asset and narrow funding leave Mindstate vulnerable if the next trial disappoints.
- Regulatory backlash against psychedelic compounds can freeze partnerships, financing, and clinician adoption.
What makes Mindstate Design Labs unique
- Mindstate turned 5-MeO-MiPT into MSD-001 with human data, not just theory.
- Their Osmanthus platform targets specific altered states, not generic psychedelic intoxication.
- A deep scientific team, including Carhart-Harris and Newberg, strengthens translational credibility.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards